Payment overview · 2025
General Payments
$1,342.59
31 reported records · 16 companies
Healthcare provider profile · identity verified
Kelli Anne Larson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · POLSON, MT · NPI 1629336953
Verified facts
What the public records show
CMS Open Payments records show Kelli Anne Larson, D.O. received $1,342.59 in general payments during 2025 across 31 reported records.
Abbott Laboratories accounted for 60.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $814.96 | 60.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $107.88 | 8.0% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.99 | 5.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.82 | 3.5% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $41.17 | 3.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.87 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.77 | 2.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.53 | 2.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.84 | 1.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.20 | 1.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.22 | 1.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.44 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.41 | 1.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.76 | 1.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.70 | 1.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.03 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $814.96 | 2 |
| Food and Beverage | $527.63 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $814.96 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $107.88 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.63 | 3 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $41.17 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $41.17 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.77 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.77 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 266 | 64 |
| Gabapentin | Gabapentin | 182 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 166 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 130 | suppressed |
| Lisinopril | Lisinopril | 128 | 31 |
| Losartan Potassium | Losartan Potassium | 123 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 121 | 27 |
| Potassium Chloride | Potassium Chloride | 108 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 101 | 12 |
| Bupropion Xl | Bupropion Hcl | 100 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 15 |
| Omeprazole | Omeprazole | 87 | 21 |
| Jardiance | Empagliflozin | 86 | 12 |
| Tramadol Hcl | Tramadol Hcl | 84 | 11 |
| Allopurinol | Allopurinol | 81 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 81 | suppressed |
| Famotidine | Famotidine | 79 | suppressed |
| Myrbetriq | Mirabegron | 79 | suppressed |
| Ozempic | Semaglutide | 72 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | suppressed |
| Topiramate | Topiramate | 66 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 12 |
| Trazodone Hcl | Trazodone Hcl | 57 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | suppressed |
| Lovastatin | Lovastatin | 54 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 54 | 17 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Simvastatin | Simvastatin | 53 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 46 | 12 |
| Furosemide | Furosemide | 45 | 13 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 15 |
| Montelukast Sodium | Montelukast Sodium | 44 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 13 |
| Meloxicam | Meloxicam | 42 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | suppressed |
| Eliquis | Apixaban | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Metformin Hcl | Metformin Hcl | 33 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Budesonide Dr | Budesonide | 12 | suppressed |
| Budesonide Ec | Budesonide | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,342.59 · 31 records | Abbott Laboratories | AIRSUPRA, AUSTEDO XR, BEVESPI AEROSPHERE, BEYFORTUS, CARDIOMEMS, Cologuard Collection Kit, FANAPT, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, INSPIRE, Korlym, MOUNJARO, MYFEMBREE, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VAXELIS, VRAYLAR, WINREVAIR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error